Chengdu starts producing advanced antibody drugs
The launch ceremony for the Duote antibody drug production base was held at Chengdu Medical Center in Wenjiang district on April 18.
As Chengdu’s first advanced antibody drug production base, Duote has received investment from GE Healthcare and Sichuan Baili Medical Group.
According to Ding Ning, deputy director of Wenjiang district government, Chengdu Medical Center in Wenjiang has been focusing on promoting the research and development of innovative drugs, medical equipment and modern Chinese medicine.
The construction project for the drug production base has two stages. The first stage has received an investment of 180 million yuan ($26.15 million) and has a total area of 6,000 square meters. The second stage of the project will receive investment of $100 million and is expected to finish construction in 2020.
In recent years, the country has made great efforts in supporting the pharmaceutical industry. Local authorities in Wenjiang have enacted policies to accelerate the integration of medical sciences, treatment and production of pharmaceuticals. As planned, Wenjiang will further promote the cross-industry integration of biomedicine and information technology.
Source from China Daily